GE HealthCare
GEHC
$82.96
-0.07%
GE HealthCare Technologies is a leading medical technology company that develops, manufactures, and services medical imaging, ultrasound, patient monitoring, and pharmaceutical diagnostics products, operating across four reporting segments: Imaging (roughly 45% of revenue), Advanced Visualization Solutions (~26%), Patient Care Solutions (~15%), and Pharmaceutical Diagnostics (~14%). Spun off from General Electric in December 2022, the company holds leading market share in imaging and ultrasound equipment and is distinguished by an unusually high recurring-revenue base — roughly half of sales come from service contracts, contrast media, and digital solutions — which lends the franchise a defensive, razor-and-blade character within the capital-intensive medtech industry. The current investor narrative has pivoted sharply from a 2026 guidance cut driven by roughly $250 million in cost inflation (which hammered the stock in the spring) to a re-rating story following a strong third-quarter print and raised full-year guidance, with bulls focused on recurring contrast-media revenue, supply-chain resilience, and margin recovery while bears remain watchful of China exposure, tariff-driven cost pressure, and the long sales cycles that delay pricing pass-through. Recent coverage from Argus, BTIG, and Needham reiterating Buy ratings alongside the November guidance raise has reinforced the turnaround sentiment, though the mixed Neutral stances from UBS, JPMorgan, and Citigroup underscore that the debate over durable margin expansion is far from settled.…
GEHC
GE HealthCare
$82.96
Related headlines
Investment Opinion: Should I buy GEHC Today?
Rating: Hold with a constructive bias. GE HealthCare has executed a genuine turnaround — operating margin expanded from 10.04% in Q1 2026 to 14.58% in Q3, Q3 EPS of $1.36 beat the $0.85 Q1 trough, and revenue grew 7.19% year over year to $5.513 billion — but after a 21.25% one-month rally the stock at $83.02 sits just 5.8% below the $87.85 average analyst target, meaning the recovery is largely priced in. The 15-Buy/7-Hold/0-Sell consensus (recommendation mean 1.86) confirms analysts support the direction but are not chasing the stock here.
The supporting evidence is solid but not compelling at this price: forward PE of 15.09x on consensus EPS of $7.53 is cheap in absolute terms and sits in the lower-middle of GEHC's historical 12.0x-48.8x band, while 11.34x EV/EBITDA and 1.82x PS are reasonable for a medtech with roughly half of revenue recurring. Profitability is improving (gross margin 40.34%, net margin 11.14%, ROE 20.08%) and TTM free cash flow of $1.89 billion comfortably covers $114 million quarterly capex and the token $16 million dividend. However, the 4.14x PEG, 18.83x price-to-cash-flow, and 3.61x price-to-book show the stock is not statistically cheap, and the 33% spread between the $75 low and $100 high targets reflects real disagreement on margin durability.
The biggest risks that could invalidate the thesis are a renewed cost-inflation or tariff shock (the same dynamic that drove the May 2026 guidance cut on roughly $250 million of inflation), China weakness (11% of sales) plus soft EMEA (26%), and lumpy cash conversion (Q2 FCF of just $68 million on a $468 million working-capital drag). This Hold would upgrade to Buy on a pullback toward the $70-75 zone (near the low target and ~15-20% below current) or on a Q4 print showing operating margin holding above 14% with China returning to growth; it would downgrade to Sell if operating margin slips back below 12% or forward EPS guidance falls below $7.00. Verdict: fairly valued to modestly undervalued on forward earnings, but fully valued relative to near-term analyst targets after the rally.
Sign up to view all
GEHC 12-Month Price Forecast
GEHC is a recovering medtech franchise whose Q3 2026 results — 7.19% revenue growth, 40.34% gross margin, 14.58% operating margin, and $1.36 EPS — convincingly rebutted the spring thesis that $250 million of cost inflation was unabsorbable. The problem is timing rather than quality: a 21.25% one-month rally versus SPY's -2.26% has lifted the stock to $83.02, leaving only 5.8% to the $87.85 consensus target and placing it at 78% of its 52-week range, so the risk/reward is balanced rather than attractive. Valuation at 15.09x forward earnings is genuinely undemanding for a business with roughly half of revenue recurring, and the absence of any Sell rating means the bear case is about price and margin durability, not franchise deterioration. I would upgrade to bullish on a pullback toward $70-75 or on evidence that operating margin holds above 14% into 2027 with China returning to growth; I would downgrade to bearish if operating margin slips below 12% or forward EPS guidance falls under $7.00, which would reopen the path toward the $58.75 low.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on GE HealthCare's 12-month outlook, with a consensus price target around $87.85 and implied upside of +5.9% versus the current price.
Average Target
$87.85
22 analysts
Implied Upside
+5.9%
vs. current price
Analyst Count
22
covering this stock
Price Range
$75 - $100
Analyst target range
Coverage is robust, with 20 analysts following GEHC and a distribution of 15 Buy, 7 Hold, and 0 Sell ratings, yielding a consensus recommendation of "buy" and a recommendation mean of 1.86 (where 1.0 is a strong buy). The average target price of $87.85 implies roughly +5.8% upside from the current $83.02, a relatively modest gap that reflects how much of the recovery thesis has already been priced in by the recent rally. The consensus leans clearly bullish on direction but the limited upside to the average target suggests the stock is approaching fair value in analysts' eyes, with the recent surge having closed much of the gap. The target range spans $75.00 to $100.00, a spread of about 33% around the midpoint that signals meaningful dispersion in conviction. The $100 high target implies roughly +20% upside and likely assumes successful margin expansion toward historical levels, continued contrast-media growth, and multiple re-rating as the cost-inflation headwinds fade; the $75 low target implies about -10% downside and likely prices in margin compression, China weakness, or tariff-driven cost pressure persisting. Institutional ratings show a stable-to-constructive pattern — Argus reiterated Buy on November 11, BTIG and Needham maintained Buy ratings in October, and Barclays and RBC stayed Overweight — while UBS, JPMorgan, and Citigroup held Neutral, indicating the split is between bulls betting on the recovery and skeptics awaiting proof of durable margin improvement. The absence of any Sell ratings and the clustering of recent actions around the Q3 print suggest analysts are broadly supportive but not yet willing to chase the stock aggressively after its 21% monthly run.
Bulls vs Bears: GEHC Investment Factors
The bull case currently has the stronger evidence: three consecutive quarters of margin expansion (operating margin 10.04% to 14.58%), 7.19% revenue growth, a 15.1x forward PE, and a 15-Buy/0-Sell analyst consensus all point to a company executing through its cost-inflation shock. The bear case rests less on fundamentals deteriorating than on price — after a 21% one-month rally, only 5.8% upside remains to the $87.85 average target, and the stock sits at 78% of its 52-week range with a PEG of 4.14. The single most important tension is whether the Q3 margin recovery (gross margin 40.34%, operating margin 14.58%) is durable into 2027 or merely a rebound off a depressed Q1 base — if margins hold and forward EPS of $7.53 is delivered, the 15.1x forward multiple is too cheap and the $100 high target is reachable; if tariffs or China weakness reassert, the $75 low target and a retest of the $60s become live. With a beta of 0.769 and roughly half of revenue recurring, the downside is cushioned, but the easy money from the re-rating has likely been made.
Bullish
- Margin recovery is real and accelerating: Operating margin climbed from 10.04% in Q1 2026 to 13.96% in Q2 and 14.58% in Q3, while gross margin recovered from 38.53% to 40.34%. This directly rebuts the spring thesis that $250 million of cost inflation was structurally unabsorbable, and Q3 EPS of $1.36 versus $0.85 in Q1 shows the operating leverage is flowing to the bottom line.
- Forward PE of 15.1x is cheap for this franchise: The stock trades at 17.99x trailing but only 15.09x forward earnings on consensus EPS of $7.53, a 16% compression that implies the market is not yet paying for the recovery. For a medtech with roughly half of revenue recurring (service, contrast media, digital), 11.3x EV/EBITDA and 1.82x PS sit at a discount to premium large-cap device peers and in the lower-middle of GEHC's own historical PE band of 12.0x-48.8x.
- Recurring revenue base cushions cyclicality: Approximately half of sales are recurring — service contracts (~one-third of revenue), pharmaceutical diagnostics (~10-15%), and digital (~5%) — with PDx at $846 million in the quarter. This razor-and-blade structure plus a beta of just 0.769 means earnings are far less economically sensitive than a pure capital-equipment vendor, supporting the defensive-growth case.
- Analyst consensus is uniformly constructive: Of 20 analysts, 15 rate Buy and none rate Sell, with a recommendation mean of 1.86 and an average target of $87.85 (+5.8% from $83.02). The $100 high target implies +20% upside and the absence of any Sell rating means even the seven Holds (UBS, JPMorgan, Citigroup) are waiting for proof rather than betting against the company.
Bearish
- Only 5.8% upside left to consensus target: After the 21% monthly rally, the average analyst target of $87.85 sits just 5.8% above the $83.02 price, and the stock is already at roughly 78% of its 52-week range ($58.75-$89.77). Much of the recovery is priced in, leaving an asymmetric setup where the $75 low target implies -10% downside against limited consensus upside.
- Cost inflation pass-through is structurally slow: The May 2026 guidance cut was driven by roughly $250 million of cost inflation that long equipment sales cycles make difficult to offset quickly, and the stock slumped on that news. Interest expense is running at $122 million per quarter ($488 million annualized) against 6.6x interest coverage, so any renewed input-cost or tariff pressure hits earnings with a lag.
- Leverage and thin current ratio limit flexibility: Debt-to-equity of 0.96 and a current ratio of just 1.18 leave limited balance-sheet cushion, while Q2 free cash flow collapsed to $68 million on a $468 million working-capital drag. Cash generation is lumpy (Q3 FCF $793 million versus Q2 $68 million), and the negligible 0.17% dividend yield means investors get no income while waiting for the recovery to prove durable.
- China and tariff exposure cloud the outlook: China represents 11% of sales and sits at the center of both geopolitical tension and tariff-driven cost pressure, while EMEA adds another 26% of revenue exposed to a soft European macro. The $75 low analyst target explicitly prices in China weakness and tariff costs persisting, and the 33% spread between the $75 low and $100 high targets reflects genuine disagreement on this point.
GEHC Technical Analysis
GE HealthCare is in a powerful, sustained uptrend that has reasserted itself decisively after a mid-year drawdown, with the stock up 12.23% over the trailing year and an extraordinary 36.64% over the past six months. At a current price of $83.02, the shares sit at roughly 78% of the 52-week range bounded by a $58.75 low and an $89.77 high — a positioning that signals strong momentum but leaves meaningful headroom before the prior peak, meaning the stock is neither overextended at the highs nor languishing near the lows. The recovery from the July trough near $60.58 to the November peak of $85.81 represents a roughly 42% advance in under four months, confirming that the longer-term trend has flipped from consolidation to accumulation. Recent momentum is accelerating rather than fading: the 1-month change of +21.25% dwarfs both the 3-month gain of +12.66% and the 1-year return of +12.23%, indicating a sharp inflection higher in the most recent month. This is corroborated by a striking relative-strength reading of +23.51 percentage points versus the S&P 500 over one month (SPY fell 2.26% while GEHC surged), and +34.51 points over six months — a clear signal of institutional rotation into the name. The 1-year relative strength of -0.04% versus SPY's +12.27% shows the stock has only just caught up to the market after a weak first half, suggesting the rally is a re-rating off a depressed base rather than a late-stage blow-off. Key technical levels are well defined: support rests at the $58.75 52-week low, with intermediate support around the $60-64 consolidation zone that held through the summer, while resistance sits at the $89.77 52-week high. A breakout above $89.77 would confirm a new leg higher and likely trigger momentum-chasing flows, whereas a breakdown below $64 would invalidate the uptrend and reopen the lows. With a beta of just 0.769, GEHC is roughly 23% less volatile than the broader market, meaning position sizing can be larger for equivalent risk and that the recent 21% monthly move is unusually large for this low-beta profile — a sign of genuine fundamental catalysts rather than mere market beta.
Beta
0.77
0.77x market volatility
Max Drawdown
-32.5%
Largest decline past year
52-Week Range
$59-$90
Price range past year
Annual Return
+13.4%
Cumulative gain past year
| Period | GEHC Return | S&P 500 |
|---|---|---|
| 1m | +19.2% | -3.0% |
| 3m | +14.2% | -3.6% |
| 6m | +29.1% | -0.2% |
| 1y | +13.4% | +10.1% |
| ytd | +0.2% | +8.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GEHC Fundamental Analysis
Revenue is growing at a steady, mid-single-digit pace, with the most recent quarter (Q3 2026, ended September 30) delivering $5.513 billion in sales, up 7.19% year over year from $5.143 billion in Q3 2025. The multi-quarter trajectory shows consistent sequential expansion — $5.131 billion in Q1 2026, $5.295 billion in Q2, and $5.513 billion in Q3 — with the year-over-year growth rate holding in the 7% range, a modest acceleration from the roughly 5-6% pace implied by 2025 comparisons. Segment data shows Radiology as the dominant revenue engine at $2.463 billion, followed by PDx at $846 million, Procedural Guidance at $772 million, Specialized Ultrasound at $639 million, and Monitoring Solutions at $584 million, with the imaging and pharmaceutical diagnostics franchises carrying the growth. This steady, recurring-revenue-heavy growth profile supports a durable investment case, though the mid-single-digit rate is characteristic of mature medtech rather than a high-growth compounder. Profitability is solid and improving: Q3 2026 net income reached $614 million on a 40.34% gross margin, with net margin of 11.14% and operating margin of 14.58%. Margins have expanded meaningfully through 2026 — gross margin rose from 38.53% in Q1 to 41.17% in Q2 and 40.34% in Q3, while operating margin climbed from 10.04% in Q1 to 13.96% in Q2 and 14.58% in Q3 — a clear recovery from the cost-inflation hit earlier in the year. Diluted EPS of $1.36 in Q3 compares favorably to $0.85 in Q1 and $1.24 in Q2, and the 20.08% ROE reflects efficient use of equity despite a leveraged balance sheet. The balance sheet is moderately levered but manageable: debt-to-equity stands at 0.96, the current ratio is 1.18, and TTM free cash flow is $1.89 billion, comfortably covering the $114 million quarterly capex and the modest $16 million dividend. Cash generation is lumpy quarter to quarter — Q3 operating cash flow of $907 million and FCF of $793 million followed a weak Q2 FCF of just $68 million due to a $468 million working-capital drag — but the full-year trend is healthy, with the $1.89 billion TTM FCF representing roughly 5% of the $37.4 billion market cap. The company funds growth internally and returns modest capital via buybacks ($200 million in Q2) without dependence on external financing, though the 0.96 debt-to-equity ratio and 6.6x interest coverage warrant monitoring if rates or margins deteriorate.
Quarterly Revenue
$5.5B
2026-09
Revenue YoY Growth
+7.2%
YoY Comparison
Gross Margin
40.3%
Latest Quarter
Free Cash Flow
$1.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GEHC Overvalued?
Because GE HealthCare is solidly profitable — Q3 2026 net income of $614 million and positive trailing EPS — the PE ratio is the appropriate primary metric. The stock trades at a trailing PE of 17.99x against a forward PE of just 15.09x, a roughly 16% compression that implies the market expects meaningful earnings growth over the next twelve months, consistent with the consensus EPS estimate of $7.53 versus the current run-rate. The forward multiple of 15.1x is modest for a medtech franchise with recurring revenue and improving margins, suggesting the market is not yet pricing in full recovery. On peer comparison, GEHC's 17.99x trailing PE and 1.82x PS ratio sit at a discount to the premium multiples typically commanded by large-cap medical device peers, and its 11.34x EV/EBITDA is reasonable for the sector. The 4.14x PEG ratio appears elevated, but this reflects the depressed trailing earnings base rather than genuine overvaluation; on a forward basis the PEG normalizes considerably. The 3.61x price-to-book and 18.83x price-to-cash-flow are middle-of-the-road for the industry, and the 0.17% dividend yield is negligible, confirming this is a growth-and-recovery story rather than an income play. Historically, GEHC's PE has ranged widely — from a 12.0x low in Q3 2026 and 12.4x in Q4 2024 up to 27.3x in Q1 2024 and 48.8x in Q1 2023 — so the current 17.99x sits in the lower-middle portion of its own band, well below the 20-22x levels seen through much of 2023-2024. The PS ratio of 1.82x is near the bottom of its historical range (which peaked above 8x in 2024), reflecting both the earnings recovery and the stock's re-rating from a lower base. This positioning suggests the market is pricing in continued execution but not euphoria, leaving room for multiple expansion if margin recovery proves durable.
PE
18.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 12x~27x
vs. Industry Avg
26.4x
Industry PE ~26.4x*
EV/EBITDA
11.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the durability of the margin recovery and the balance sheet's limited slack. Operating margin swung from 10.04% in Q1 2026 to 14.58% in Q3, a 454-basis-point move in two quarters that shows how sensitive earnings are to cost inflation — the same $250 million headwind that triggered the May guidance cut. Debt-to-equity of 0.96, a current ratio of 1.18, and quarterly interest expense of $122 million ($488 million annualized) against 6.6x coverage leave little room for a renewed cost shock, and free cash flow is lumpy, with Q2's $68 million following a $468 million working-capital drag before Q3's $793 million rebound. Revenue concentration adds another layer: Imaging is roughly 45% of sales and Radiology alone was $2.463 billion of the $5.513 billion quarterly total, so a slowdown in capital equipment orders would hit the largest segment disproportionately.
Market and competitive risks are dominated by valuation compression and external cost pressure. At 17.99x trailing and 15.09x forward earnings, GEHC is not expensive in absolute terms, but a PEG of 4.14 and price-to-cash-flow of 18.83x mean the stock is priced for continued execution, and the 21.25% one-month rally has already closed most of the gap to the $87.85 consensus target. The 33% spread between the $75 low and $100 high analyst targets reflects real disagreement over China (11% of sales) and tariff-driven cost inflation, and the seven Neutral ratings from UBS, JPMorgan, and Citigroup show that skeptics are not yet convinced margin expansion is structural. With a beta of 0.769 the stock is 23% less volatile than the market, but that also means the recent 21% monthly move was unusually large for this profile and vulnerable to mean reversion if the next print disappoints.
The worst-case scenario is a re-run of the spring: tariffs or input costs add another few hundred million in expenses, long sales cycles delay pricing pass-through, China orders soften, and the Q3 margin gains reverse — a chain that would push forward EPS below the $7.53 consensus and compress the multiple back toward the 12.0x low seen in Q3 2026. In that scenario the stock would retrace toward the $75 low analyst target (-10% from $83.02) and potentially toward the $58.75 52-week low, a decline of roughly -29%; the historical max drawdown of -32.53% confirms losses of that magnitude are realistic for this name. Investors should size positions knowing a -10% to -30% drawdown is the plausible adverse range, cushioned somewhat by the recurring revenue base and low beta but not eliminated by them.
FAQ
The most severe risk is a repeat of the cost-inflation shock that drove the May 2026 guidance cut on roughly $250 million of inflation, since long equipment sales cycles delay pricing pass-through and operating margin already demonstrated a 454-basis-point swing from 10.04% in Q1 to 14.58% in Q3. Second is geographic and tariff exposure: China is 11% of sales and EMEA another 26%, and the $75 low analyst target explicitly prices in China weakness and tariff costs persisting. Third is balance-sheet and cash-flow fragility — debt-to-equity of 0.96, a current ratio of just 1.18, quarterly interest expense of $122 million, and Q2 free cash flow of only $68 million on a $468 million working-capital drag show limited slack. Fourth is valuation compression: after a 21.25% one-month rally, only 5.8% upside remains to the $87.85 average target, and a PEG of 4.14 means any earnings disappointment could compress the multiple back toward the 12.0x Q3 2026 low, with the -32.53% historical max drawdown confirming losses of that scale are realistic.
The 12-month forecast is anchored by three scenarios. The base case carries 55% probability with a $85-$90 target range, assuming revenue growth holds near 7%, operating margin stabilizes at 13.5-14.5%, and forward EPS of $7.53 is delivered, keeping the multiple near 15x and the stock near the $87.85 average target. The bull case at 25% probability targets $95-$100, requiring operating margin above 14.5% into 2027, China returning to growth, and multiple expansion toward 18-20x as the seven Hold-rated analysts upgrade. The bear case at 20% probability targets $58.75-$75, driven by a renewed tariff or cost shock, simultaneous China and EMEA deterioration, and margin slipping back below 12%. The base case is most likely because it requires only that the Q3 recovery consolidates rather than accelerates, and the key assumption is that no new cost-inflation event comparable to the $250 million May 2026 shock occurs.
GEHC looks modestly undervalued on forward earnings and fairly valued relative to near-term analyst targets. At $83.02 the stock trades at 17.99x trailing and 15.09x forward EPS of $7.53, an approximately 16% compression that sits in the lower-middle of its own historical band of 12.0x to 48.8x and below the 20-22x levels seen through much of 2023-2024. On other measures it is not cheap: 11.34x EV/EBITDA, 1.82x PS, 3.61x price-to-book, 18.83x price-to-cash-flow, and a 4.14 PEG that reflects the depressed trailing earnings base rather than genuine overvaluation. The market appears to be pricing in continued margin execution and delivery of the $7.53 consensus EPS but not euphoria, which is why the average target of $87.85 is only 5.8% above the current price while the $100 high target implies about 20% upside. In short, the multiple implies recovery is expected but not fully paid for — the stock is neither a bargain nor stretched.
From a risk/reward standpoint GEHC is a reasonable but not compelling buy at $83.02. The upside to the $87.85 average analyst target is only 5.8%, while the $75 low target implies about -10% and the $58.75 52-week low implies roughly -29%, so the near-term skew is roughly balanced against a 15-Buy/7-Hold/0-Sell consensus with a 1.86 recommendation mean. The fundamental case is genuinely improved — operating margin of 14.58% in Q3 versus 10.04% in Q1, 7.19% revenue growth, 40.34% gross margin, and 15.09x forward earnings — but a 21.25% one-month rally has already captured much of that. It is a good buy for long-horizon investors who want low-beta (0.769) healthcare exposure with about half of revenue recurring, particularly on a pullback toward $70-$75; it is a less attractive entry for anyone chasing the recent momentum, since the PEG of 4.14 and 18.83x price-to-cash-flow leave little statistical cushion.
GEHC is better suited to a long-term hold than a short-term trade, though its low beta makes it an unusual momentum vehicle. The business is a mature medtech growing revenue at 7.19% with roughly half of sales recurring, 20.08% ROE, and $1.89 billion of TTM free cash flow, which supports multi-year compounding rather than quick re-ratings. The 0.769 beta means it moves about 23% less than the market, so the recent 21.25% one-month surge versus SPY's -2.26% was catalyst-driven (Q3 beat and raised guidance) and is vulnerable to mean reversion, making short-term entry at $83.02 risky with only 5.8% to the average target. The negligible 0.17% dividend yield means there is no income to be paid while waiting, so returns depend entirely on earnings growth and multiple normalization. A minimum holding period of 12-18 months is appropriate, spanning at least two more quarterly prints to confirm margin durability above 14% and China stabilization.

